Novartis submits supplemental NDA for Afinitor Disperz (NDA203985)
Novartis has submitted a supplemental NDA for Afinitor Disperz (NDA203985) with a standard review priority.
Asset / Drug
Drug and asset intelligence for Afinitor Disperz with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
mTOR Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.